We highly recommend enabling Javascript while using the BlackBoxRX site.

Panobinostat lactate

Fatal and Serious Toxicities: Severe Diarrhea and Cardiac Toxicities

  • Severe diarrhea occurred in 25% of FARYDAK treated patients. Monitor for symptoms, institute anti-diarrheal treatment, interrupt FARYDAK and then reduce dose or discontinue FARYDAK. (5.1)
  • Severe and fatal cardiac ischemic events, severe arrhythmias, and ECG changes have occurred in patients receiving FARYDAK. Arrhythmias may be exacerbated by electrolyte abnormalities. Obtain ECG and electrolytes at baseline and periodically during treatment as clinically indicated. (5.2)

Approved Risk Evaluation and Mitigation Strategies (REMS)

Farydak (Panobinostate) histone deactylase inhibitor

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts

Panobinostat lactate

Additional Information

Updated January 2018